Stibbe advises Lundbeck

Stibbe advises Lundbeck

Stibbe advises Lundbeck

29.03.2018 NL law

Stibbe advised Lundbeck on the acquisition of Prexton Therapeutics BV for an amount of up to EUR 905 million.

Lundbeck (listed on the Copenhagen Stock Exchange in Denmark) is a global pharmaceutical company specialising in psychiatric and neurological disorders with a focus on Alzheimer's disease, depression, Parkinson's disease and schizophrenia.


Related experience

This website uses cookies. Some of these cookies are essential for the technical functioning of our website and you cannot disable these cookies if you want to read our website. We also use functional cookies to ensure the website functions properly and analytical cookies to personalise content and to analyse our traffic. You can either accept or refuse these functional and analytical cookies.

Privacy – en cookieverklaring